Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash from Financing Activities (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Cash from Financing Activities for 5 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 98.41% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $104.6 million through Dec 2025, up 44.47% year-over-year, with the annual reading at $104.6 million for FY2025, 44.47% up from the prior year.
  • Cash from Financing Activities hit $1.1 million in Q4 2025 for ARS Pharmaceuticals, down from $100.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $193.8 million in Q4 2022 to a low of -$1.6 million in Q3 2022.
  • Historically, Cash from Financing Activities has averaged $21.4 million across 5 years, with a median of $823000.0 in 2023.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 1151.35% in 2022 and later surged 14612.5% in 2025.
  • Year by year, Cash from Financing Activities stood at $52.8 million in 2021, then soared by 266.95% to $193.8 million in 2022, then crashed by 99.07% to $1.8 million in 2023, then soared by 3828.86% to $70.9 million in 2024, then plummeted by 98.41% to $1.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for SPRY at $1.1 million in Q4 2025, $100.0 million in Q3 2025, and $2.7 million in Q2 2025.